 - To test if prophylactic cranial radiotherapy delivering 30 Gy in 10 fractions will significantly reduce from 35 to 21 at 2 years the incidence of symptomatic brain metastases in patients treated with trastuzumab Herceptin for metastatic breast cancer. 